Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Images
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Snippets
Special Article
Specialty Interface
Studies
Study Letter
Study Letters
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
Therapy Letters
View Point
Viewpoint
What’s new in Dermatology
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Images
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Snippets
Special Article
Specialty Interface
Studies
Study Letter
Study Letters
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
Therapy Letters
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Letter To Editor
2008:74:3;263-265
doi: 10.4103/0378-6323.41379
PMID: 18583801

Suprapharmacologic doses of intravenous dexamethasone followed by cyclosporine in the treatment of toxic epidermal necrolysis

Reena Rai, CR Srinivas
 Department of Dermatology, PSG Hospitals, Coimbatore, India

Correspondence Address:
C R Srinivas
Department of Dermatology, PSG Hospitals, Peelamedu, Coimbatore - 641 004
India
How to cite this article:
Rai R, Srinivas C R. Suprapharmacologic doses of intravenous dexamethasone followed by cyclosporine in the treatment of toxic epidermal necrolysis. Indian J Dermatol Venereol Leprol 2008;74:263-265
Copyright: (C)2008 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

Toxic epidermal necrolysis (TEN) is a widespread, life-threatening, mucocutaneous disease usually due to drugs, but vaccinations, malignancy, and graft versus host disease (GVHD) have also been implicated. [1] It may also be idiopathic in which it is not possible to identify any cause. TEN represents epidermal detachment involving more than 30%. The pathogenesis involves cytotoxic-mediated immune reaction targeted at the destruction of keratinocytes expressing foreign antigens. [2] It has been shown that in the fluid contained in the bullae of patients with TEN, T-lymphocytes predominate in the initial phases, while subsequently the cells of the monocyte-macrophagic line prevail and probably contribute to the progression of the necrosis through TNF production. [3] Epidermal keratinocytes express large amounts of Fas ligand (CD95L), and interaction between these and Fas (CD95) on the effector cells are directly in epidermal necrolysis. [4] The role of genetic factors in the pathogenesis of TEN remains to be clarified. The onset of TEN usually occurs 7-21 days after the beginning of medical treatment, and the rare cases of relapse initiate within 48 hrs of taking the drug, thus suggesting the existence of an immunological memory. The various modalities of treatment include steroids, cyclosporine, intravenous immunoglobulin, thalidomide, cyclophosphamide, pentoxifylline, N acetyl cysteine, and plasmapherisis. [5] The use of corticosteroids is a much-debated question.

Some reports have described a dramatic improvement in patients with TEN treated with corticosteroids. [6],[7] Steroids can be given intravenously or as suprapharmacologic doses intravenously. Short-term use of suprapharmacologic intravenous doses of dexamethasone, at an early stage of the disease, may contribute to a reduced mortality rate in SJS/TEN without increasing the healing time. [8] Use of steroids modifies the cell-mediated immune response in the pathogenesis of TEN. Cyclosporin inhibits the principal cellular populations involved in the pathogenesis of TEN (activated T-lymphocytes, macrophages, keratinocytes), interferes with the metabolism of TNF, and possesses an anti-apoptosis property that causes the death of keratinocytes in TEN. [9] We report three patients of TEN who were treated with suprapharmacologic doses of intravenous dexamethasone followed by cyclosporine.

Case 1: A 40-year-old male presented with TEN after therapy with phenytoin for epilepsy since 1 month. The diagnosis was confirmed by histopathology with frozen sections and H and E-stained sections. He was nursed in isolation and was administered intravenous with 100mg of dexamethasone in 5% glucose for 4 days till no new lesions appeared. Cyclosporine was started on day 5 at the dose of 2 mg/kg weight till the patient′s general condition improved, and then tapered at the dose of 50mg every 3 rd day, and stopped after 2 weeks when the patient had complete remission and re-epithelization of skin lesions.

Case 2: A 55-year-old female presented with TEN after carbamazepine. After confirmation of the diagnosis by frozen section, she was administered 100mg of dexamethasone in 5% glucose for 2 days, when no new lesions appeared. Cyclosporine was administered on day 3 in the same regime as in Case 1.

Case 3: A 22-year-old female presented with TEN after ciprofloxacin. After confirming the diagnosis on frozen sections and H and E-stained sections of skin biopsy, she was administered suprapharmacologic doses of intravenous dexamethasone in the form of 100mg of dexamethasone in 5% glucose for 2 days, when no new lesions appeared. Cyclosporine was administered on day 3 in the same regime as in Case 1.

All three patients were taken in succession and treated in isolation in a tertiary care hospital, where the clinical diagnosis of TEN was confirmed by frozen and H and E sections of skin biopsy. Once the diagnosis of TEN was confirmed by frozen sections, treatment was started on the same day, even when new lesions were appearing. In all patients, electrolytes and input-output chart were monitored. In addition, supportive treatment like antibiotics, fluid replacement, daily dressing, and nutritional support was given.

The treatment of TEN in a burn unit or in isolation has considerably improved patients′ prognosis and survival. Appropriate care and nursing, such as protection of the cutaneous and mucosal surfaces involved, monitoring of the electrolytic balance, fluid replacement, nutritional support, and the prevention and treatment of infection, are the mainstays of treatment. Steroids help to arrest the disease progress by modifying the cell-mediated immune response and preventing the progression of the disease when given within 72 hours. [6] By administering steroids early and for a short duration, the side-effects like gastrointestinal bleeding, delayed wound healing, and increased risk of infection can be prevented. Since cyclosporine has anti-apoptosis property and decreases the time taken for complete re-epithelization, it helps arrest further progression of the disease. [10],[11]

Although steroids could have been continued till the person recovered, the risk of septicemia and other associated complications due to steroids is reported to increase mortality. Since the role of steroids is in the early phase and does not have any effect after 72 hrs, the steroids given early and for a short duration may help improve the prognosis. Since cyclosporine is reported to be effective in TEN by interrupting the disease progression and decreasing the time taken for complete re-epithelization, we feel that the combination of initial high dose of steroid and subsequent cyclosporine will be a safe alternative to treat this condition associated with high mortality.

Hence, to reduce mortality in toxic epidermal necrolysis, suprapharmacologic doses of intravenous corticosteriods at an early stage of the disease, followed by cyclosporine, appear to be a rational option to influence the immune system, which leads to apoptosis and necrolysis, and results in early recovery.

Suprapharmacologic doses of intravenous dexamethasone, given at an early stage of the disease, contribute to a reduced mortality rate and modify the cell-mediated immune response in the pathogenesis of TEN. Cyclosporin possesses an anti-apoptosis property that causes the death of keratinocytes in TEN. By using a combination of both, the immune response is modified and the side-effects of steroids are minimized, and the disease progression is interrupted by cyclosporine. This combination may be a safe alternative in the management of TEN.

References
1.
Wolkenstein PE, Roujeau JC, Revuz J. Drug induced toxic epidermal necrolysis. Clin Dermatol 1998;16:399-409.
[Google Scholar]
2.
Revuz JE, Roujen JC. Toxic epidermal necrolysis. Cutaneous Medicine of Surgery. WB Saunders Press; 1995. p. 704-11.
[Google Scholar]
3.
Paquet P, Pierard GE. Soluble fraction of tumour necrosis factor-a, interleukin-6 and their receptors in toxic epidermal necrolysis. Arch Dermatol 1998;130:605-8.
[Google Scholar]
4.
Viard I, Wehrli, Bullani R, Salomon D, Saurat JH, French LE. Inhibition of toxic epidermal necrolysis by blockage of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3.
[Google Scholar]
5.
Sharma VK. Guidelines for Stevens-Johnson syndrome and toxic epidermal necrolysis and psoriasis. Therapeutic Guidelines Committee Indian Association of Dermatologists Venereologists and Leprologists. Delhi: IADVL; 2007. p. 7-19.
[Google Scholar]
6.
Fine JD. Management of acquired bullous skin diseases. N Eng J Med 1995;333:1475-84.
[Google Scholar]
7.
Cheriyan S, Patterson R, Greenberger PA. The outcome of Stevens-Johnson syndrome treated with corticosteroids. Allergy Proc 1995;16:151-5.
[Google Scholar]
8.
Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derma Venereol 2007;87:144-8.
[Google Scholar]
9.
Paquet P, Pierard GE. Would cyclosporin A be beneficial to mitigate drug-induced toxic epidermal necrolysis? Dermatology 1999;198:198-202.
[Google Scholar]
10.
Criton S. Toxic epidermal necrolysis: A retrospective study. Int J Dermatol 1997;36:923-5.
[Google Scholar]
11.
Arevalo JM, Lorente JA, Herrada G, Jimenez-Reys J. Treatment of toxic epidermal necrolysis with cyclosporine. J Trauma 2004;48:473-8.
[Google Scholar]

Fulltext Views
701

PDF downloads
469
Show Sections